Auspex Pharmaceuticals, a late-stage biotech developing treatments for CNS disorders, raised the proposed deal size for its upcoming IPO on Tuesday. The San Diego, CA-based company now plans to raise $66 million by offering 6.0 million shares at a price range of $10 to $12. The company had previously filed to offer 5.5 million shares at the same range. At the midpoint, Auspex Pharmaceuticals would raise 9% greater proceeds than previously anticipated.
Auspex Pharmaceuticals, which was founded in 2001, plans to list on the NASDAQ under the symbol ASPX. Auspex Pharmaceuticals initially filed confidentially on November 21, 2013. Stifel and BMO Capital Markets are the joint bookrunners on the deal. It is expected to price during the week of February 3, 2014.
